Trimel Pharmaceuticals Corporation
TSX : TRL

Trimel Pharmaceuticals Corporation

October 27, 2011 13:00 ET

Trimel Pharmaceuticals Corporation to Report Third Quarter 2011 Results and Host a Conference Call

TORONTO, CANADA--(Marketwire - Oct. 27, 2011) - Trimel Pharmaceuticals Corporation (TSX:TRL) will report on the third quarter results for the Company and its subsidiaries for the period ended September 30, 2011 on Wednesday, November 2, 2011 after the market closes.

Management of the Company will host a conference call to discuss these results on Thursday, November 3, 2011, at 8:30 a.m. Eastern Time. Presenting from Trimel will be Bruce Brydon, Chairman of the Board and Chief Executive Officer, and Kenneth Howling, Chief Financial Officer.

To access the call live, please dial 416-340-2219 (Toronto), 1-866-226-1798 (Canada and U.S.), and 00-800-9559-6849 (International). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.

A replay of the conference call will be available until 7:00 p.m. Eastern Time on Thursday, November 10, 2011 by dialing 905-694-9451 (Toronto), 1-800-408-3053 (Canada and U.S.) or 00-800-3366-3052 (International), using access code: 4012435#.

For further information regarding Trimel Pharmaceuticals Corporation, please contact either Bruce Brydon at 416-679-0711 or Kenneth Howling at 416-679-0536 or via email at ir@trimelpharmaceuticals.com.

About Trimel

Trimel Pharmaceuticals Corporation (TSX:TRL) - Developing medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT, a bio-adhesive intranasal Testosterone gel for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit www.trimelpharmaceuticals.com.

Contact Information

  • Trimel Pharmaceuticals Corporation
    Kenneth G. Howling
    Chief Financial Officer
    416 679 0536